Dronedarone Hydrochloride and Patiromer Sorbitex Calcium
Determining the interaction of Dronedarone Hydrochloride and Patiromer Sorbitex Calcium and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR CLOSELY: Dronedarone may cause dose-related prolongation of the QT interval. Since hypokalemia and hypomagnesemia are known risk factors for arrhythmia associated with QT prolongation, coadministration of dronedarone with agents that can cause significant potassium and/or magnesium loss (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may increase the risk of ventricular arrhythmias such as torsade de pointes and sudden death. MANAGEMENT: Caution is advised if dronedarone must be used concomitantly with medications that can cause significant potassium and/or magnesium loss. Serum electrolytes should be evaluated at baseline and at regular intervals throughout the duration of therapy. Any abnormalities should be corrected prior to initiating therapy, and levels should be maintained within the normal range during treatment. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Dronedarone should be discontinued if QTc Bazett interval increases to 500 ms or greater. References "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ.
Professional:MONITOR CLOSELY: Dronedarone may cause dose-related prolongation of the QT interval. Since hypokalemia and hypomagnesemia are known risk factors for arrhythmia associated with QT prolongation, coadministration of dronedarone with agents that can cause significant potassium and/or magnesium loss (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may increase the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
MANAGEMENT: Caution is advised if dronedarone must be used concomitantly with medications that can cause significant potassium and/or magnesium loss. Serum electrolytes should be evaluated at baseline and at regular intervals throughout the duration of therapy. Any abnormalities should be corrected prior to initiating therapy, and levels should be maintained within the normal range during treatment. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Dronedarone should be discontinued if QTc Bazett interval increases to 500 ms or greater.
- "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ.
Generic Name: dronedarone
Brand name: Multaq
Synonyms: Dronedarone
Generic Name: patiromer
Brand name: Veltassa
Synonyms: Patiromer
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dronedarone Hydrochloride-Pavacot
- Dronedarone Hydrochloride-Paxil
- Dronedarone Hydrochloride-Paxil (Paroxetine Suspension)
- Dronedarone Hydrochloride-Paxil (Paroxetine Tablets)
- Dronedarone Hydrochloride-Paxil CR
- Dronedarone Hydrochloride-Pazopanib
- Patiromer Sorbitex Calcium-Droperidol
- Patiromer Sorbitex Calcium-Droperidol Injection
- Patiromer Sorbitex Calcium-Drospirenone
- Patiromer Sorbitex Calcium-Drospirenone and estradiol
- Patiromer Sorbitex Calcium-Drospirenone and ethinyl estradiol
- Patiromer Sorbitex Calcium-Drospirenone, ethinyl estradiol, and levomefolate